

Scientific Advisory Board appointment – Dr. Rakesh Veedu

Delivering drug cargoes across cell membranes is the major challenge in the development of a revolutionary new class of drugs. Cell Penetrating Peptides (CPPs) can overcome this challenge and provide access to the 'undruggable genome' – the highest value drug targets that exist inside cells. Phylogica (ASX:PYC) owns the world's most structurally diverse peptide library and is using these libraries to identify a new generation of highly efficient CPPs.

22 March 2019: Phylogica is pleased to advise that it has appointed Dr. Rakesh Veedu to its Scientific Advisory Board (SAB). Dr. Veedu is the head of precision nucleic acid therapeutics research at the Centre for Comparative Genomics at Murdoch University. Dr. Veedu joins Professor Judy Lieberman (Harvard), Professor Shohei Koide (NYU) and Dr. Steve Doberstein (Nektar Therapeutics) on Phylogica's SAB.

Dr. Veedu is an expert in Antisense Oligonucleotides – the class of gene targeting drug molecules that Phylogica has prioritised in the development of its Cell Penetrating Peptide (CPP) technology. 'We are very pleased to welcome Dr. Veedu to our SAB – his expertise in chemistry & chemical biology will be very helpful for us as we progress towards clinical development of our technology' commented Phylogica's CEO Dr. Rohan Hockings. 'Working together in the joint development of CPP-ASO molecules with local collaborators who are also globally recognised leaders in the field is an important part of our path to the clinic'.

ENDS

For further information, please contact:

Rohan Hockings
CEO
roanhockings@phylogica.com

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and screening its peptide libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetrating peptides has been validated across multiple animal models for the ability to deliver a diverse range of drug cargoes into cells. The company has collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and Genentech.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

www.phylogica.com

Phylogica Ltd

ABN 48 098 391 961